Equities analysts predict that Fibrocell Science Inc (NASDAQ:FCSC) will post ($0.52) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Fibrocell Science’s earnings. Fibrocell Science posted earnings per share of ($0.33) in the same quarter last year, which would suggest a negative year over year growth rate of 57.6%. The firm is expected to issue its next quarterly earnings results on Thursday, March 8th.

On average, analysts expect that Fibrocell Science will report full-year earnings of ($2.58) per share for the current year. For the next year, analysts forecast that the business will report earnings of ($1.23) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that cover Fibrocell Science.

Several brokerages recently commented on FCSC. Canaccord Genuity reiterated a “buy” rating and set a $7.00 price target (up from $3.00) on shares of Fibrocell Science in a report on Monday, September 11th. ValuEngine downgraded shares of Fibrocell Science from a “sell” rating to a “strong sell” rating in a report on Wednesday, September 6th. Zacks Investment Research upgraded shares of Fibrocell Science from a “sell” rating to a “hold” rating in a report on Friday, September 22nd. Finally, HC Wainwright upped their price target on shares of Fibrocell Science from $5.70 to $7.60 and gave the company a “buy” rating in a report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $5.21.

In related news, major shareholder Randal J. Kirk bought 2,727,273 shares of the company’s stock in a transaction on Monday, December 11th. The shares were acquired at an average cost of $0.77 per share, for a total transaction of $2,100,000.21. The purchase was disclosed in a filing with the SEC, which is available through this link. 2.10% of the stock is owned by corporate insiders.

A hedge fund recently bought a new stake in Fibrocell Science stock. Pura Vida Investments LLC acquired a new stake in shares of Fibrocell Science Inc (NASDAQ:FCSC) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 297,000 shares of the company’s stock, valued at approximately $909,000. Pura Vida Investments LLC owned approximately 2.02% of Fibrocell Science as of its most recent filing with the Securities & Exchange Commission. 55.81% of the stock is currently owned by institutional investors.

Fibrocell Science (NASDAQ:FCSC) opened at $0.69 on Tuesday. Fibrocell Science has a fifty-two week low of $0.61 and a fifty-two week high of $4.64.

COPYRIGHT VIOLATION WARNING: “Brokerages Expect Fibrocell Science Inc (FCSC) to Post -$0.52 EPS” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/19/brokerages-expect-fibrocell-science-inc-fcsc-to-post-0-52-eps.html.

About Fibrocell Science

Fibrocell Science, Inc is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related.

Get a free copy of the Zacks research report on Fibrocell Science (FCSC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fibrocell Science (NASDAQ:FCSC)

Receive News & Ratings for Fibrocell Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science and related companies with MarketBeat.com's FREE daily email newsletter.